ICDD is a biotech company and mitochondrial expert that provides the healthcare industry with innovative proprietary screening platforms to better achieve targeted research to accelerate drug development and bring greater benefits to the patient.
ICDD believes that by helping reduce product development costs by developing and making available the appropriate decision-making tools and product development technologies, researchers will be encouraged to tackle some of the more difficult to treat diseases that are associated with high overall costs to society, such as neurodegenerative diseases.
ICDD operates 2 distinct pharmaceutical business units:
A partnering research organization (PRO), which offers a state-of-the-art research facility and an experienced team to help pharmaceutical companies of all sizes identify drug safety and efficacy using innovative in vitrohuman models for CNS diseases, cancer, anti-virals, cardio-protection, and metabolic indications. An R&D unit focused on personalized medicine and diagnostics for CNS diseases, with a particular attention to patient stratification and the identification of pre-dementia stages of neurodegeneration.
ICDD also helps researchers in the cosmetic industry better understand the mechanisms by which healthy aging and personnal care can be promoted through the engagement of the mitochondrial network function and behavior. ICDD is the ideal partner to the cosmetic industry to scientifically substantiate commercial claims for active ingredients using
Innovation, expertise, confidence
Proprietary platforms providing decision-making tools adapted to the fast-pace required by the industry.
More than 60 years of combined scientific experience to respond to your needs in lead discovery and optmization, safety assessment, and identification of mechanisms of action.
Our technologies have yielded products successfully developed in clinical phase that have obtained EMA and FDA approval and/or are on market. Our business includes a large proportion of returning customers, which reflects the quality of our science and the degree of satisfaction achieved.
Key dates and milestones
ICDD was founded by 4 scientists who believed that generating decision tools enabling optimization of development processes for
Cellulomic technology was used to generate translatable patient-derived cell models.
Mitochondrial liabilities are recognized as one of the causes for previously unrecognized drug toxicity responsible for phase 2 drug failures (Dykens & Will,
ICDD's Mitosafe® technology provides bioassays to analyze mitochondrial liabilities in non-permeabilized live cells.
Category “Espoir création-incubation”
Expansion of Mitosafe®'s reach and portfolio of services to document mechanisms of action of products targeting mitochondria using Bioenergetics, Redox status and mtDNA content markers.
Initial love money round of 400K€ completes 1.2 million € of non-dilutive funding.
ICDD's Mitostream cellulomic technology is used for modelling & diagnostic tool development in CNS diseases (AD and HD).
ICDD's Cellesis toxicity profiler is industrially validated through independent benchmarking with the Drug Safety Executive Council.
ICDD develops blood markers to identify pre-dementia stages of AD through a partnership with Assistance Publique Hôpitaux de Marseille.
ICDD becomes a partner of the Pharmacog IMI consortium for the validation of MCI patient stratification tools.
Round A of 800K€ secured with the participation of Grand Delta, Var BA, PACA Investissement/Turenne management.
ICDD's team's scientific expertise in mitochondrial testing is recognized in the global market of health products with clients in Europe, the USA, and Asia in the pharmaceutical, phyto-chemical, nutraceutic, and cosmetic markets.
First drug tested through the Cellesis toxicity profiler reaches market and makes millions!
The MJFF supports ICDD for it's Parkinson's disease models and marker development.
ICDD moves to its new facility in Gemenos (2400 sq ft., lab and offices).
Initial proof of principal of superior performances of ADflag® blood diagnostic panel with respect to stratification of patients suffering from pre-dementia cognitive loss.
Our scientific team
The scientists at ICDD boast a combined experience of more than 60 years in drug development, biochemistry, cell biology and neuroscience, having analyzed more than 100s of new chemical entities at different stages of their development.